Rapid Progressive Glioblastoma despite Radiation in a Patient with Myelodysplastic Syndrome
暂无分享,去创建一个
[1] E. Wong,et al. Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma , 2020, Molecular and clinical oncology.
[2] E. Wong,et al. Dexamethasone-Friend or Foe for Patients With Glioblastoma? , 2019, JAMA neurology.
[3] M. Sperandio,et al. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells , 2018, Oncoimmunology.
[4] B. Nahed,et al. Sequestration of T-cells in bone marrow in the setting of glioblastoma and other intracranial tumors , 2018, Nature Medicine.
[5] M. Mehta,et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 , 2018, Neuro-oncology.
[6] P. Fecci,et al. T-cell Dysfunction in Glioblastoma: Applying a New Framework , 2018, Clinical Cancer Research.
[7] G. Garcia-Manero,et al. Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management , 2018, American journal of hematology.
[8] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[9] A. List,et al. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. , 2017, Seminars in hematology.
[10] V. Levin,et al. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma , 2015, Journal of Neuro-Oncology.
[11] R. Weichselbaum,et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.
[12] M. Delorenzi,et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.
[13] S. Piantadosi,et al. Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.
[14] R. Weichselbaum,et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. , 2011, Cancer research.
[15] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[16] Lei Wu,et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. , 2009, Microvascular research.
[17] E. Operskalski,et al. Screening of blood donors for idiopathic CD4+ T‐lymphocytopenia , 1994, Transfusion.